⚡ NVDA CEO Huang sells $79.7M in stock; market awaits earnings
Published Mar 23, 2026
We read 77 filings today. Here are the ones worth your time.
63 Form 414 8-K38 Buys22 Sells
NVDA's Jen-Hsun Huang just filed on $79.7 million worth of stock. That's the largest insider move in today's 77 filings.
On the buy side, HORIZON KINETICS ASSET MANAGEMENT added TPL while insiders at ZTS, ETN, and PNW also picked up shares. CVS saw a sale from director Gallina.
Nvidia CEO Jensen Huang sold $79.7M in shares through a 10b5-1 plan with the stock at $172.93, down 8% year-to-date but still holding near the upper end of its 52-week range of $87-$212. The predetermined plan removes discretion from the timing, though the size stands out as Huang continues methodical sales even as shares trade 18% below their recent peak. The transaction comes amid broader tech volatility and ongoing questions about AI infrastructure spending sustainability.
Huang's continued selling through scheduled plans reflects standard executive diversification, yet the timing coincides with Nvidia trading at depressed levels relative to its 2024 highs despite record data center revenue. The AI chip leader faces mounting competition from custom silicon efforts at major cloud providers and new entrants like AMD, making sustained margin leadership less certain. Executives selling near 52-week highs would be routine, but $79.7M in sales while shares sit 18% below peak suggests either exceptional confidence in personal liquidity management or awareness that current valuations already price in optimistic scenarios.
Director Gallina bought $42K of CVS at $71, a modest stake as the stock trades mid-range after a 10% YTD decline. The pharmacy giant faces persistent margin pressure from its PBM business and rising medical costs in its insurance division. Small insider buys rarely move the needle, but this one comes as the company refocuses on core healthcare after shelving retail expansion plans.
EVP Ruiz Sternadt sold $40K of Eaton shares at $357, just 13% below the all-time high of $408. The industrial conglomerate has surged 54% from its 52-week low as data center power demand drives electrical systems orders. The modest sale size barely registers for a C-suite executive at a company now commanding a $140 billion market cap.
VP Mark Stetter bought $25K of ZTS at $116, just above the 52-week low as the stock trades down 33% from its peak. The animal health leader faces pressure from weaker pet care spending and China headwinds. This marks insider buying near a critical support level after months of selling across the sector.
Horizon Kinetics dropped $527 into TPL at $519, barely below the 52-week high of $547. The firm has consistently praised TPL's royalty model in letters to investors as oil production climbs across the Permian Basin. This micro-position looks like an add-on to an existing stake rather than a fresh conviction call.
CEO Heflin sold $1.8M of PNW at $97, just 7% below the 52-week high of $104. The utility has climbed 11% this year on steady rate increases and renewable energy investments. His first sale in six months comes as valuation reaches the upper end of the peer group range.
EVP Teter unloaded $12.1M worth of NVDA at $173, down 18% from its $212 peak hit just weeks ago. The sale comes as AI chip demand faces growing scrutiny from hyperscalers managing capital spending. Teter's last major exit in early 2024 preceded a 15% pullback before the stock rebounded.
Former CFO Shoquist unloaded $11.9M in NVDA stock at $173, just 18% off the all-year high despite the 8% year-to-date decline. The timing follows peak AI chip demand that drove shares up 140% over the past year. Insiders rarely exit this aggressively unless they see margin compression ahead.
Fortive entered a new credit agreement creating a direct financial obligation, though specific terms were not disclosed in the filing. The move comes while shares trade mid-range at $55, suggesting the company is securing financing during stable market conditions rather than distress. Investors should monitor upcoming earnings calls for details on how management plans to deploy this capital, whether for acquisitions or operational investments.
Labcorp entered into a new credit agreement creating a direct financial obligation, as disclosed in its latest 8-K filing. The diagnostic testing giant is restructuring its balance sheet while trading near mid-range of its 52-week band at $263. The timing suggests the company is positioning for operational flexibility as the post-pandemic testing revenue mix normalizes. Investors should monitor upcoming earnings for updates on debt deployment strategy.
Fair Isaac entered a new credit agreement providing $2.5B in financing facilities to refinance existing debt and support general operations. The timing follows FICO's 31% stock decline this year, likely giving management flexibility for capital deployment as shares trade near 52-week lows. The refinancing improves debt maturity structure while maintaining the company's capacity for buybacks or strategic investments.